Kinnate Biopharma Inc. Sells Its Investigational Pan-RAF Inhibitor, exarafenib, to Pierre Fabre Laboratories
- Written by PR Newswire
![]() |
- Kinnate has entered into an Asset Purchase Agreement (the "APA") with Pierre Fabre Laboratories for global rights to exarafenib and other pan-RAF program assets.
- The transaction is in furtherance of Kinnate's previously announced pursuit of strategic alternatives.
- This acquisition is intended to enable Pierre Fabre Laboratories to pursue its efforts...















